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Abstract
Background: There are sparse data on the long-term and late effects of hematopoietic cell transplantation (HCT) for sickle cell
disease (SCD).
Objective: This study aims to establish an international registry of long-term outcomes post-HCT for SCD and demonstrate
the feasibility of recruitment at a single site in the United States.
https://www.researchprotocols.org/2022/7/e36780
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Methods: The Sickle Cell Transplantation Evaluation of Long-Term and Late Effects Registry (STELLAR) was designed to
enroll patients with SCD ≥1 year post-HCT, their siblings without SCD, and nontransplanted controls with SCD to collect
web-based participant self-reports of health status and practices by using the Bone Marrow Transplant Survivor Study (BMTSS)
surveys, health-related quality of life (HRQOL) using the Patient-Reported Outcomes Measurement Information System (PROMIS)
Pediatric Profile-25 or Pediatric Profile-29 survey, chronic graft-versus-host disease (cGVHD) using the symptom scale survey,
daily pain using an electronic pain diary, the economic impact of HCT using the financial hardship survey, sexual function using
the PROMIS Sexual Function SexFSv2.0 survey, and economic productivity using the American Time Use Survey (ATUS). We
also piloted retrieval of clinical data previously submitted to the Center for International Blood and Marrow Transplant Research
(CIBMTR); recorded demographics, height, weight, blood pressure, waist and hip circumferences, timed up and go (TUG) test,
and handgrip test; and obtained blood for metabolic screening, gonadal function, fertility potential, and biorepository of plasma,
serum, RNA, and DNA.
Results: Of 100 eligible post-HCT patients, we enrolled 72 (72%) participants aged 9-38 (median 17) years. We also enrolled
19 siblings aged 5-32 (median 10) years and 28 nontransplanted controls with SCD aged 4-46 (median 22) years. Of the total
119 participants, 73 (61%) completed 85 sets of surveys and 41 (35%) contributed samples to the biorepository. We completed
ATUS interviews of 28 (24%) participants. We successfully piloted retrieval of data submitted to the CIBMTR and expanded
recruitment to multiple sites in the United States, Canada, the United Kingdom, and Nigeria.
Conclusions: It is feasible to recruit subjects and conduct study procedures for STELLAR in order to determine the long-term
and late effects of HCT for SCD.
International Registered Report Identifier (IRRID): DERR1-10.2196/36780
(JMIR Res Protoc 2022;11(7):e36780) doi: 10.2196/36780
KEYWORDS
anemia; sickle cell; late effect; hematopoietic cell transplantation; web-based registry; sickle cell disease; transplant; protocol

Introduction
Hematopoietic cell transplantation (HCT) remains the only
treatment undertaken with curative intent for sickle cell disease
(SCD). HCT has the possibility of alleviating disease-related
morbidity, improving physical function, stabilizing organ
function, and improving the quality of life [1,2]. The results of
HCT for SCD from human leukocyte antigen (HLA)-identical
sibling donors are excellent, with over 94% overall survival and
91% event-free survival [3-8]. Alternative donor HCT [5,9-13]
and autologous gene therapy (GT) can further increase the
applicability of HCT for SCD [9,14-16]. Observational case
series, clinical trials, and research registries have typically
captured the short- and intermediate-term outcomes of
engraftment, graft-versus-host disease (GVHD), and survival
1-3 years post-HCT. However, the late effects of HCT, including
detailed patient-reported outcomes (PROs), physical function,
health status, health behaviors, and health outcomes, have not
been captured. In addition, approximately 10% of post-HCT
mortality after HCT for SCD occurs beyond 5 years after HCT
[6]. Therefore, there is potential for persistent or new late
morbidity following HCT for SCD. These observations provide
a rationale for the systematic study of long-term and late effects
to understand the impact of allogeneic HCT and autologous GT
on patients' life course and outcomes.
The impact of HCT in SCD can be better understood by
comparing the long-term outcomes in the post-HCT group with
those in their siblings without SCD and in nontransplanted
persons with SCD matched for age, genotype, and disease
characteristics that define the propensity to undergo HCT.
Siblings share social, psychological, and environmental
exposures and may share genetic predispositions. Thus, this
comparison group provides the best approximation of how the
https://www.researchprotocols.org/2022/7/e36780
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participants may have fared had they not been born with SCD.
In contrast, nontransplanted individuals with SCD matched for
age, gender, and propensity to undergo HCT provide the best
estimate of what may have been the outcomes of post-HCT
patients had they not undergone HCT. Unfortunately, no such
contemporaneous comparison cohort has been established to
date, despite the awareness of this knowledge gap.
We designed the Sickle Cell Transplantation Evaluation of
Long-Term and Late Effects Registry (STELLAR) to address
this knowledge gap and track and compare the long-term
outcomes and late effects of HCT for SCD compared to
unaffected sibling controls and nontransplanted patients with
SCD. We implemented the registry in collaboration with the
Center for International Blood and Marrow Transplant Research
(CIBMTR) and core centers experienced in the conduct of HCT
for SCD. Our overarching hypothesis is that HCT for SCD
improves the health-related quality of life (HRQOL) and immune
function but is associated with gonadal damage and impaired
fertility potential compared to nontransplanted controls with
SCD and sibling controls without SCD. Our objectives were to
(1) compare the long-term HRQOL, pain, financial hardship,
physical function, health status, health behaviors, and economic
productivity; (2) compare gonadal function and fertility status
in adults post-HCT for SCD with these contemporaneous
comparison groups; and (3) leverage current data collected
through the CIBMTR to harmonize data collection and avoid
duplication of effort in the field. This report describes
STELLAR’s design and development and its pilot testing and
implementation in participating pediatric and adult programs
in Atlanta, GA, USA.
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Methods
Study Design
STELLAR is a prospective, longitudinal, observational tool
comparing health outcomes in study participants post-HCT for
SCD, siblings without SCD, and a contemporary group of
nontransplanted subjects with SCD.

Ethics
The study was approved by the Western Institutional Review
Board (IRB), which served as the single IRB for the study
(approval number WIRB 20200372). All the study procedures
followed were in accordance with the ethical standards of the
responsible committee on human experimentation (institutional
and national) and with the Declaration of Helsinki of 1975, as
revised in 2000.

Krishnamurti et al

Participants
The inclusion criteria were (1) patients with SCD of any age
>1 year post-HCT or autologous GT; (2) HLA-matched donor
siblings for post-HCT participants or a sibling without SCD of
the recipient who is closest in age for the recipient of the
transplant from an HLA-matched unrelated donor,
HLA-haploidentical related donor, or autologous GT; and (3)
patients with SCD (Hemoglobin SS [HbSS] or Hemoglobin
S/β0 Thalassemia [HbSβ0]) who have not undergone HCT.
The exclusion criterion was non-English-speaking individuals.

Setting
The study was designed as a collaboration among several sites
with substantial experience and expertise in performing HCT
for SCD (Textbox 1) for the recruitment of subjects through
direct contact and in clinic settings.

Textbox 1. Participating sites.
•

Emory University, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, GA, USA

•

Emory University Department of Hematology, Grady Hospital, Atlanta, GA, USA

•

Children's National Health Systems, Washington, DC, USA

•

Columbia University Medical Center, NY, USA

•

Cook Children's Medical Center, TX, USA

•

Alberta Children’s Hospital, Calgary, Canada

•

Children's Hospital of Los Angeles, CA, USA

•

Imperial College Healthcare, London

•

National Heart, Lung, and Blood Institute, Bethesda, MD, USA

•

University of North Carolina, NC, USA

•

Lagos University Teaching Hospital, Lagos, Nigeria

•

Duke University, NC, USA

•

Washington University School of Medicine, MO, USA

•

Baylor College of Medicine, TX, USA

Recruitment of Individuals Post-HCT for SCD
We reviewed electronic medical records to identify individuals
who underwent allogeneic HCT or autologous GT or follow-up
care in the participating centers. Then, using the last-known
contact information, we approached potential participants by
mail, email, and telephone. For participants currently <18 years
old, we approached their parents/legal guardians for
participation. In the case of potential study participants ≥18
years old, we contacted them directly. When we did not have
the correct contact information for potential participants, we
used social media and people-finding software to establish
contact with those individuals. In addition, we organized annual
reunions of survivors and their families to raise awareness of
the study. Participants aged ≥18 years were also offered
participation in the reproductive health substudy to assess sexual
function and reproductive health. Individuals post-HCT for
SCD were also approached when they attended an ex-sickle
clinic, a clinic designated for long-term follow-ups of patients
with successful HCT for SCD.
https://www.researchprotocols.org/2022/7/e36780
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Recruitment of Nontransplanted Controls With SCD
After establishing procedures for enrollment of transplant
recipients, we sequentially expanded enrollment to siblings
without SCD and nontransplanted participants with SCD.
Nontransplanted patients with SCD were approached for study
in a comprehensive sickle cell clinic. Patients and siblings were
also approached in annual post-HCT reunions and through social
media. In the case of minor siblings, we contacted their parents
to obtain informed consent. In the case of adult siblings, we
received permission from HCT survivors or their parents to
contact the siblings.
We piloted the enrollment of pediatric and adult nontransplanted
patients with SCD in the pediatric and adult sickle cell programs
in Atlanta, GA, USA. Since registration is ongoing and
participants are of a wide age range, we enrolled control subjects
regardless of age to establish a pool of control patients. For
matching post-HCT participants to nontransplanted individuals,
we will select age, gender, and the propensity score matched to
post-HCT patients. We will use logistic regression for propensity
JMIR Res Protoc 2022 | vol. 11 | iss. 7 | e36780 | p. 3
(page number not for citation purposes)

JMIR RESEARCH PROTOCOLS
score calculation from the following variables: (1) the number
of episodes of acute chest syndrome, (2) the frequency of
hospitalization for a vaso-occlusive crisis in the 2 years
pre-HCT, and (3) a history of stroke. A 1:1 propensity score
matching will be performed using the nearest-neighbor-matching
method with a caliper width fixed at 0.2. Propensity score
matching will be performed using JMP Pro 13.2.0 (SAS Institute
Japan, Co, Ltd, Tokyo, Japan).

Study Procedures
The study procedures included medical record review, data
retrieval from the CIBMTR, participant-completed surveys and
electronic pain diaries, fertility evaluation, clinical parameters,
vital measurements, physical function tests, and blood samples
for metabolic screening, gonadal and fertility potential, and
biobanking specimens.

Clinical Parameters and Vital Measurements
We recorded clinical parameters, including vital signs, and
measurements, including height, weight, and waist and hip
circumferences. In addition, we performed a handgrip test, a
measure of the maximum isometric strength of hand and forearm
muscles and the widely used general muscle strength [17-20],
a timed up and go (TUG) test [21,22], and a test of mobility
and balance as assessments of physical function [17-19]. We
will repeat these procedures annually.

Surveys
We used a set of validated surveys to capture patient reports of
health outcomes, health practices, and the HRQOL (Table 1).
The Bone Marrow Transplant Survivor Study (BMTSS) survey
[23,24] is a measure that has been extensively validated for use
in long-term survivors of BMT to capture patient reports of
health, health practices, health interventions, and complications
[23-25].
The patient report on this survey was validated against medical
records and was found to be accurate. The BMTSS surveys
contain 130 items that ask questions on health status regarding
hearing, vision, speech, and urinary tract; hormonal, heart and
circulatory, respiratory, digestive, and brain and nervous
systems; cancer; offspring; and pregnancy. The surveys also
address health habits and practices related to alcohol or
substance abuse, school history, employment history, and
insurance. We reduced the burden of completing BMTSS
surveys by using branching logic, also known as skip logic,
which creates a custom pathway based on a user's response and
accordingly presents subsequent questions, thus allowing the
user to skip a question that does not apply to them.
Patients <18 years old completed the Patient-Reported Outcomes
Measurement Information System (PROMIS) Pediatric

https://www.researchprotocols.org/2022/7/e36780
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Profile-25 survey. This survey assesses 6 HRQOL domains (ie,
mobility, anxiety, depression, fatigue, peer relationships, and
pain interference) by asking 4 questions per domain [26-30].
There is a single item on pain intensity. Patients >18 years old
completed the PROMIS Pediatric Profile-29 v2.0 survey [31,32],
which assesses pain intensity by a single question on a 0-10
rating scale and 6 health domains (ie, physical function, fatigue,
pain interference, depressive symptoms, anxiety, and ability to
participate in social roles and activities) and sleep disturbance
using 4 questions per domain. Adults also completed the
stiffness subscale of the Adult Sickle Cell Quality of Life
Measurement Information System (ASCQ-Me) [29,33-35].
All patients with SCD completed the sickle cell self-efficacy
survey [26-30,36] containing 9 questions relating to participants'
perceptions of their ability to function daily and manage SCD
symptomatology [36,37]. In addition, transplant recipients
completed the chronic graft-versus-host disease (cGVHD)
symptom survey and financial hardship assessments. The
cGVHD symptom scale is a 30-item scale with 7 subscales to
capture the cGVHD-specific burden [38,39].
To determine the impact of HCT on financial hardship, including
income, employment, and insurance status, we adapted a 43-item
measure developed at the Dana Farber Cancer Institute (DFCI)
and used in stem cell transplant economic impact studies [40,41].
We modified the survey to a 38-question patient-reported
financial hardship assessment tool. In addition, we adapted the
survey for use in a pediatric population with parent proxy and
age-appropriate patient surveys.
Study participants completed surveys electronically. The
application is adaptable for use on smartphones, tablets, or
computers and is platform “agnostic.” Participants can start,
stop, and save completion of surveys at will. To further
minimize the burden of survey completion, we split the surveys
into 4 parts and gave participants the option of completing these
surveys quarterly over the year. To reduce the burden for
completion in subsequent years, the response fields are
automatically populated with draft responses from previous
years. Participants are prompted to accept or change the response
to proceed to the next screen. We incorporated a page timer in
the surveys to track the amount of time spent by participants in
each survey.
Our hypothesis was that those with SCD have lower rates of
participation in economic activity and spend more time in
health-related activities than the African American population
in general as well as patients with SCD who are long-term
survivors of HCT for SCD. To test this hypothesis, we piloted
the American Time Use Survey (ATUS), a structured
computer-assisted telephone interview.
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Table 1. Surveys completed and average time taken to complete them.
Description of scale

Average time to complete

Health and health practice surveys for all age groups (total time for the first quarter: 11 min 31 s)
Demographics

1 min 17 s

School history

1 min 7 s

Employment history

1 min 2 s

Insurance

51 s

PROMISa Adult Profile v2.0 or PROMIS Pediatric Profile-25 v2.0

6 min 36 s

ASCQ-Meb stiffness

26 s

Health and health practice surveys for all age groups (total time for the second quarter: 8 min 13 s)
cGVHDc

1 min 38 s

Previous encounters

45 s

Family history

4 min 46 s

Marital status

52 s

Religion

7s

Health and health practice surveys for all age groups (total time for the third quarter: 5 min)
Hearing and speech

41 s

Urinary system

13 s

Hormonal system

35 s

Health and circulatory system

40 s

Respiratory system

29 s

Digestive system

31 s

Brain and nervous system

1 min 53 s

Health and health practice surveys for all age groups (>total time for the fourth quarter: 11 min 6 s)
Financial survey

5 min 26 s

Health habits

1 min 32 s

Surgical procedures

59 s

Medical care

1 min 19 s
d

e

Other issues (SCD SEQ-C )

22 s

Financial survey

2 min

Reproductive Health Survey (HCTf recipients and controls with SCD aged >18 years only)
PROMIS Sexual Function SEXFSv2.0

7 min

Service utilization and cost (transplant recipients and controls with SCD)
GAINg Scale

3 min

Financial burden of HCT
DFCIh finances and employment scale

3 min

ATUSi
Economic productivity
a

30-45 min interview

PROMIS: Patient-Reported Outcomes Measurement Information System.

b

ASCQ-Me: Adult Sickle Cell Quality of Life Measurement Information System.

c

cGVHD: chronic graft-versus-host disease.

d

SCD: sickle cell disease.

e

SCD SEQ-C: Sickle Cell Disease Self-Efficacy Questionnaire for Children.
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f

HCT: hematopoietic cell transplantation.

g

GAIN: Global Assessment of Individual Needs.

h

DFCI: Dana Farber Cancer Institute.

i

ATUS: American Time Use Survey.

Assessment of Reproductive Potential and Hormonal
and Sexual Function
For post-HCT patients and nontransplanted controls with SCD
who were ≥18 years old, we administered offspring and
pregnancy history surveys, reproductive health from the
BMTSS, and PROMIS sexual function and satisfaction surveys
v2.0 [7,8]. Blood samples were collected for assay of
reproductive hormones, including anti-Mullerian hormone
(AMH), luteinizing hormone (LH), follicle-stimulating hormone
(FSH), and estradiol in females and LH, FSH, and testosterone
in males. In addition, fertility potential was assessed by semen
analysis in males and the antral follicle count in females. A
STELLAR study fertility specialist interpreted reproductive
hormone labs, semen analysis, and antral follicle counts.

Data Retrieval From the CIBMTR
We collaborated closely with the CIBMTR to develop a process
for retrieving clinical data submitted by centers to the CIBMTR
before and after HCT. The CIBMTR has now established
mechanisms by which centers can recover their own submitted
data, either on an individual patient level or with data
visualizations. The CIBMTR has also collaborated with the
CureSC initiative to prepare a deidentified publicly available
data set of patients with SCD undergoing HCT. This data set
includes variables relevant to late effects, approved by a large
group of stakeholders, and standard pre-, peri-, and post-HCT
patient, disease, and demographic variables. The CIBMTR
leveraged the CureSC data set to identify patients transplanted
at the Atlanta site, and data have already been successfully
retrieved. The CIBMTR will facilitate a process to offer
participating STELLAR locations their center code to identify
their patients within the publicly available data set and merge
those data with other data at their center.
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XSL• FO
RenderX

Medical Record Data Abstraction
The clinical data unavailable or not collected by the CIBMTR
and relevant to this study were abstracted from the patients’
medical charts. We reviewed the medical records and collected
data from the clinical assessment to determine health care
utilization, disease complications, and outcomes in post-HCT
patients, non-HCT patients with SCD, donors, and healthy
sibling controls.

Pain Diary
We used a validated web-based electronic multidimensional
pain diary for collecting ecological momentary assessment
(EMA) pain data [42]. Post-HCT participants with SCD and
nontransplanted controls with SCD completed an electronic
pain diary, as described earlier, twice a day for 2 weeks each
year. Participants were asked to use the pain diary if they were
≥8 years old, had undergone HCT or autologous GT, or had
SCD. Participants were asked to begin survey completion at
their convenience and as soon as possible after study enrollment.
The items on the pain diary include pain intensity, pain location,
pain quality description, interference with sleep, mood,
work/school, daily life, interactions with friends and family,
and medications and nonpharmacological treatments for pain.
There are 5 items for morning data collection and 14 items for
evening data collection, which take approximately 5 min to
complete.

Biological Specimen Collection
Blood samples of subjects who consented were collected by
phlebotomy during the visit. The timing of blood and urine
sample collection and other study procedures is described in
Table 2. Metabolic screening was implemented with fasting
blood sugar levels, urinalysis, the complete blood count, and
the lipid profile.
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Table 2. Specimen collection: blood work and procedures.
Labs and procedures

Enrollment

Annual

Biorepositorya

✓

N/Ab

C-reactive protein

✓

N/A

Fibrinogen

✓

N/A

Troponin-I

✓

N/A

Brain natriuretic peptide (BNP)

✓

N/A

Immunoglobulin G (IgG)

✓

N/A

Fasting blood glucose

✓

✓

Glucose fructosamine

✓

✓

Insulin level

✓

✓

Urinalysis

✓

✓

Urine for microalbuminuria

✓

✓

Complete blood count with differential

✓

✓

Urine creatinine

✓

✓

Lipoprotein, serum lipids after 12 h fast

✓

✓

Immunophenotype of T, B, and natural killer (NK) cells

✓

N/A

Pneumococcal-23 serotype IgG

✓

N/A

D-dimer

✓

N/A

FSHc (≥11 years old)

✓

✓

LHd (≥11 years old)

✓

✓

AMHe (females ≥11 years old)

✓

✓

Testosterone (males ≥11 years old)

✓

✓

Estradiol (females ≥11 years old)

✓

✓

Blood urea nitrogen (BUN)

✓

✓

Creatinine

✓

✓

Thyroid panel

✓

✓

Lactate dehydrogenase (LDH)

✓

N/A

Hemoglobin electrophoresis

✓

✓

Chimerism study (HCTf patients only; fluorescent in situ hybridization [FISH] or variable number of
tandem repeats [VNTR]; not paid for by study funds)

✓

✓

Semen analysis (males enrolled in reproductive health aim)

✓

N/A

Antral follicle count by vaginal ultrasound (females enrolled in the reproductive health aim

✓

N/A

Height/weightg

✓

✓

Hip/waist circumferenceg

✓

✓

Handgriph

✓

N/A

TUGh,i

✓

N/A

Pain diaryj

✓

N/A

Surveysk

✓

✓

a

Biorepository specimen tests include testing of soluble urokinase plasminogen activator receptor (suPAR) and metabolomics to identify untargeted
and global small-molecule metabolites, functional opsonophagocytic activity, and splenic function assay with flow cytometric enumeration of Howell-Jolly
micronuclei. The biorepository specimens will be shipped to the Children’s Healthcare of Atlanta lab.
b

N/A: not applicable.
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FSH: follicle-stimulating hormone.

d

LH: luteinizing hormone.

e

AMH: anti-Mullerian hormone.

f

HCT: hematopoietic cell transplantation.

g

All participants will complete height/weight and hip/waist circumference measurements.

h

TUG: timed up and go.

i

Participants ≥4 years old will complete handgrip and TUG testing.

j

The pain diary will only be used over a 2-week period for individuals ≥8 years old who underwent HCT or autologous GTl or have SCDm. Please see
the Pain Diary section for additional details.
k

Refer to Textbox 1 and Table 1 surveys for additional information.

l

GT: gene therapy.

m

SCD: sickle cell disease.

Participant Tracking/Monitoring
Participants receive automated reminders for study procedures.
In addition, research coordinators monitor the status of
completing surveys, reach out directly to participants, and offer
reminders and technical support, as needed. We will also
continue the engagement of study participants through relevant
educational messages on the study website, personal messages
on birthdays and HCT anniversaries, and social reunions of
individuals who have undergone HCT.

Power Calculation and Analysis Plan
For adequate power to capture a range of effect sizes in the final
registry, we targeted a sample size that would be feasible to
recruit and provide adequate statistical power to detect smaller
effect sizes (eg, standardized mean difference [SMD]<0.3). To
determine whether HCT survivors differ from matched
nontransplanted patients with respect to pain, physical
functioning, and HRQoL, we would need approximately 1000
patients (500 per group) to have at least 85% power to detect a
0.20 SMD in these outcome measures among the 2 groups using
a 2-sided 2-sample t test with a type I error rate of 0.025. The
primary analysis strategy relies on the use of a propensity score.
It is possible that some patients may be missing important
baseline data, restricting their inclusion in the propensity score
analysis. However, even with 20% missing data without any
imputation, our sample size would still achieve at least 80%
power to detect a minimum effect size of 0.22 with a 0.025 type
I error rate.
Power was calculated using a 2-sample t test using Power
Analysis & Sample Size (PASS) version 14.0.8 (NCSS, LLC,
Kaysville, UT, USA). To recruit an adequate sibling cohort for
post-HCT patients with SCD, we will enroll 500 HCT survivors,
with nontransplanted patients with SCD recruited at a 1:1 ratio.
Assuming at least 75% of patients with HCT will have a sibling
control, 375 post-HCT patients with SCD with 375 sibling
controls would provide at least 80% and 85% power to detect
minimum effect sizes of 0.23 and 0.24, respectively, in the
sibling cohort samples using a 2-sided 2-sample t test with a
0.025 significance level.
An estimated 996 cases of HCT for SCD were reported between
2008 and 2017, and annually over 140 new cases are reported
to the CIBMTR [5,43]. The centers participating in this study
reported nearly half of all HCT procedures reported to the
CIBMTR to date. Further, since reporting of HCT to the
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CIBMTR was not mandatory before 2008, and some of the
participating centers do not currently report data to the
CIBMTR, there may be additional patients available for study.
Thus, for this study of the feasibility of the registry, we
estimated that if we can enroll and capture outcomes on 50%
of the eligible individuals, we would have demonstrated the
feasibility of adequate enrollment of post-HCT participants.

Results
Participant Details
We attempted to contact 100 eligible post-HCT individuals with
SCD, identified from a review of medical records at a single
center. We enrolled 72 (72%) post-HCT individuals who were
9-38 (median 17) years old and 1-29 (median 3) years old, and
63 (87%) of them had received the transplant from an
HLA-identical sibling donor. After optimizing study procedures
for transplant recipients, we sequentially opened the study to
enroll siblings without SCD and nontransplanted patients with
SCD. To date, we have enrolled 19 siblings aged 5-32 (median
10) years and have also enrolled 28 nontransplanted controls
with SCD, aged 4-46 (median 22) years. Of the 119 participants
enrolled in the study so far, 85 sets of surveys have been
completed by 73 (61%) nonduplicated participants (51 [70%]
post-HCT, 11 [15%] siblings, 11 [15%] controls), including 80
completed PROMIS HRQOL surveys. Although there was
variability in the numbers who started each of the different
surveys, there were few missing data fields overall and they
appeared random for the completed surveys. A total of 44 (61%)
post-HCT subjects with SCD (26 [59%] females, 18 [41%]
men), 10 (53%) sibling donors, and 10 (36%) nontransplanted
controls with SCD have completed the fertility-screening
surveys. In addition, hormone surveys have been completed by
63 (53%) individuals, offspring surveys by 22 (19%) individuals,
and surveys on PROMIS satisfaction with sexual function by
21 (18%) participants. Measurements of height and weight were
available on 72 (61%) individuals. To date, 41 (34%)
participants have provided research blood samples, and 20 (17%)
participants have also submitted samples on subsequent time
points. We piloted data retrieval from the CIBMTR for
post-HCT subjects with SCD enrolled in Atlanta, GA, USA.
We requested data on 52 post-HCT participants in this study
on whom data had previously been submitted to the CIBMTR;
11 (21%) subjects had not signed consent for research at the
original data submission to the CIBMTR, so no data could be
shared. Of 41 participants who had provided consent to the
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CIBMTR for using their data for research, 14 (34%) had limited
essential transplant data collected, while 27 (66%) had been
randomized to gather detailed research case report forms. The
missing data from the CIBMTR were completed by abstracting
data from electronic medical records. The study is now opening
at centers in the U.S., U.K., Nigeria, and Canada, and enrollment
at other centers has commenced. We have completed 28 (24%)
American Time Use Survey (ATUS) interviews.

Discussion
Principal Findings
We described the design and implementation of an international
registry designed to capture long-term and late effects of HCT
for SCD. Although the importance of long-term and late effects
of HCT for SCD is well recognized and consensus guidelines
for follow-up have been published, there is still a lack of data
on the subject [44-47].
Initial implementation of STELLAR at the pilot site in Atlanta,
GA, USA, suggests that such a study is feasible on a large scale.
We recruited 72 (72%) of 100 eligible post-HCT patients with
SCD at a single site even as we iteratively implemented
optimization of our methodology. Enrollment continues,
although it is impacted by interruptions in routine clinic
attendance during the COVID-19 pandemic. Nevertheless, this
invitation response rate for recruitment is comparable to the
recruitment experience of long-term survivors of HCT in the
BMTSS [48], although the participants are predominantly
African Americans and may be disadvantaged by health
disparities. Further, although several consenting patients did
not complete surveys, those who started surveys completed
them with minimal missing data.

Comparison With Previous Studies
This study was modeled on the extensively validated
methodology of the Childhood Cancer Survivor Study and the
BMTSS [24,49,50]. These studies have refined, validated, and
implemented approaches to studying of late effects of treatment.
Therefore, we adopted the best practices in the field for this
study and adapted them for electronic data capture by patients
using a computer, tablet, or smartphone. In addition, we added
validated measures of PROs, physical function, and vital
measurements.

Strengths
The CIBMTR captures data on the survival of transplant
recipients through the HCT center lifelong. The CIBMTR has
also demonstrated that centralized PRO data collection in HCT
is feasible and clinically meaningful [51]. However, individuals
with stable donor-derived erythropoiesis post-HCT are typically
no longer followed at the HCT center or to the center. This is
likely because they are no longer perceived as needing any
specialized services, are not eligible for Medicaid because they
do not have the diagnosis of SCD (for US participants), live far
from the center, or have difficulty obtaining health insurance
as adults. Thus, the HCT center may not be able to provide data
or subject access to the CIBMTR. In addition, their primary
care provider may or may not be aware of current guidelines
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on monitoring for the late effects of HCT and may not be
performing the screening procedures.
Further, since PROs are not captured during routine clinical
encounters, they cannot be retrieved by mining electronic
medical records. STELLAR is thus designed to supplement the
efforts of the CIBMTR by directly engaging post-HCT and
control study participants and enrolling and prospectively
following participants in the long term. Such an approach can
provide granular information about the health status, health
behaviors, and health outcomes throughout the life course.
Another major strength of this study is the detailed follow-up
of sexual function and fertility potential. Ovarian and testicular
dysfunction are significant concerns for patients facing
gonadotoxic therapies. The strong likelihood of loss of
reproductive potential is a substantial consideration of patients
and their caregivers considering HCT [52]. In addition, sexual
dysfunction is a concern in patients post-HCT [53], especially
females with failure to produce sex hormones. Males with SCD
who have had recurrent priapism are at risk for sexual
dysfunction. Therefore, it is crucial to understand the prevalence
of infertility, low sex hormone production, and sexual
dysfunction in all patients with SCD, including after HCT and
autologous GT. These understudied outcomes will aid in
counseling patients about expectations around reproductive
health with or without curative therapy. In addition, assessing
patient perceptions of risk for infertility or sexual dysfunction
will assist in adapting communication about reproductive health
to avoid inaccurate patient perceptions of reproductive health
risks secondary to HCT. An accurate understanding of patient
perceptions will help decision-making and promote decisional
satisfaction.

Key Lessons Learned in Implementation
In implementing STELLAR at the coordinating site in Atlanta,
GA, USA, we learned several vital lessons about recruiting and
retaining participants that helped us refine our approach. First,
after trying various strategies to reach out to post-HCT patients,
we found that the ex-sickle clinic, a clinic focused on the
long-term follow-up of survivors of HCT, provides the best
opportunity to approach potential participants. The majority of
the HCT and sibling participants were enrolled and study
procedures were carried out in the setting of an ex-sickle clinic.
Such a clinic allows study data to be collected
contemporaneously to deliver clinical care and, thus, minimizes
participant burden. Further, a sizable majority of post-HCT
patients have undergone the procedure within the past 8 years
[5]. Therefore, they are likely to retain connections to the HCT
center. Thus, they could potentially be reached at such a clinic.
Second, in piloting the study, it became apparent that completing
several surveys and repeating them annually may pose a
substantial participant burden. Therefore, we have successfully
implemented several measures to reduce participant burden,
including using branching logic, splitting surveys into multiple
parts, and allowing survey data to be carried over from year to
year, with the participant being able to review and accept or
edit the responses. Several patients who consented to participate
in the study still did not complete PROs, which underscores the
difficulties inherent in understanding what motivates participants
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to consent and remain in a registry in the long term, how to
optimize their experience, and how to communicate information
derived from the study that is of interest to them.

Limitations
There are several limitations to this study. First, we recruited
participants who remained connected to a single HCT center
with a well-established long-term follow-up in an ex-sickle
clinic. Expanding this study to the other US and international
centers with different institutional and cultural settings with
various health care models may require overcoming barriers
that may not have been foreseen. Even at this single center, we
were only able to offer the study to those patients for whom we
had a current address and who were responsive to our efforts
to reach them. Thus, our sample does not include any patients
unwilling to or unable to connect to the HCT center. Second,
we have available PROs only from participants who completed
them. Thus, we do not know the impact of selection bias and
missing data on STELLAR. To minimize this potential bias and
reach a more significant proportion of transplant recipients, we
have refined our approach to recruiting subjects directly through
internet and social media advertisements. An emerging body
of literature will guide our efforts to implement and refine
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web-based recruitment and address the ethical, regulatory, and
logistical issues related to the recruitment and retention of study
participants online [54-57]. Once we enroll subjects online, we
will also seek their consent to contact their HCT center and
obtain additional, detailed, and accurate clinical information
relevant to the study.

Conclusion
We described the design of STELLAR and the feasibility of
capturing outcomes in patients with SCD who have undergone
HCT or GT, their siblings without SCD, and nontransplanted
patients with SCD. We also reported the critical lessons learned
from refining the study design and optimizing study processes
at the lead site in Atlanta, GA, USA. In addition, we have taken
essential steps to establish methods for retrieving data submitted
to the CIBMTR and harmonizing data collection. Thus,
STELLAR provides a model for the longitudinal collection of
critical data on the long-term outcomes of HCT and
contemporaneous comparison cohorts, which are vital for future
studies of allogeneic HCT and autologous GT. The necessary
next steps will be the participation of sites worldwide, with
ongoing feasibility evaluation of multisite participation.
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DFCI: Dana Farber Cancer Institute.
EMA: ecological momentary assessment
FSH: follicle-stimulating hormone
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